Sugi Predict

Sugi Predict / Compounds / SCHEMBL2486938

SCHEMBL2486938

SCHEMBL2486938

COc1ccc(Cn2ncc3c4c(cnc32)CCc2nc(S(C)(=O)=O)ncc2-4)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ HPGD P15428 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ PDE1B Q01064 5/20 0.38
▸ PDE1A P54750 3/20 0.38
▸ PDE1C Q14123 3/20 0.38
▸ NPBWR1 P48145 5/20 0.36
▸ CNR2 P34972 3/20 0.36
▸ MCHR1 Q99705 1/20 0.34
▸ MET P08581 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ ACVR1B P36896 1/20 0.34
▸ TGFBR1 P36897 1/20 0.34
▸ ACVRL1 P37023 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2490576 0.83 ALDH1A1 (0.41) ALDH1A1LMNAMAPTSMN1; SMN2HPGD
SCHEMBL2490215 0.83 ALDH1A1 (0.43) ALDH1A1LMNAMAPTSMN1; SMN2HPGD
SCHEMBL2804966 0.78 ALDH1A1 (0.45) ALDH1A1LMNAMAPTSMN1; SMN2HPGD
SCHEMBL13273412 0.78 ALDH1A1 (0.41) ALDH1A1LMNAMAPTSMN1; SMN2HPGD
SCHEMBL2806808 0.77 ALDH1A1 (0.44) ALDH1A1LMNAMAPTSMN1; SMN2HPGD
SCHEMBL2803963 0.77 ALDH1A1 (0.43) ALDH1A1LMNAMAPTSMN1; SMN2HPGD
SCHEMBL2805918 0.76 MAPT (0.43) ALDH1A1LMNAMAPTSMN1; SMN2HPGD
SCHEMBL2804194 0.76 PDE1A (0.43) ALDH1A1LMNAMAPTSMN1; SMN2HPGD
SCHEMBL2512329 0.76 ALDH1A1 (0.48) ALDH1A1LMNAMAPTSMN1; SMN2HPGD
SCHEMBL1355303 0.76 NPBWR1 (0.46) ALDH1A1LMNAMAPTSMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 — — US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 — — US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 — — US disclosed
EP-2379551-A1 SUBSTITUTED PYRAZOLO [3, 4-B]PYRIDINE COMPOUNDS ArQule, Inc. (US) 2011-10-26 — — EP disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 — — US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 — — US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 — — US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 — — WO disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 ALDH1A1 460/4885LMNA 1591/4885MAPT 3332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.